UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000048976
Receipt number R000055799
Scientific Title Evaluation of the effects of combined consumption of test foods containing plant-derived bioactive substances on the biomarker in blood
Date of disclosure of the study information 2022/09/21
Last modified on 2023/12/20 10:00:16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of the effects of combined consumption of test foods containing plant-derived bioactive substances on the biomarker in blood

Acronym

Evaluation of the effects of combined consumption of test foods containing plant-derived bioactive substances on the biomarker in blood

Scientific Title

Evaluation of the effects of combined consumption of test foods containing plant-derived bioactive substances on the biomarker in blood

Scientific Title:Acronym

Evaluation of the effects of combined consumption of test foods containing plant-derived bioactive substances on the biomarker in blood

Region

Japan


Condition

Condition

Healthy subjects

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effects of combined ingestion of plant-derived bioactive substances on blood biomarker concentrations. In addition, the effect of combined ingestion of plant-derived bioactive substances on appetite will be evaluated as the secondary endpoints.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Blood biomarker concentrations

Key secondary outcomes

Appetite score, nutrient intake


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration


Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Intake the test food and drink for 3 weeks

Interventions/Control_2

Intake the placebo food and drink for 3 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1) Subjects who are males and females over 20 years old and under 65 years old
2) Subjects who can use the electronic logbook application
3) Subjects who agree to participate in this study with a written informed consent

Key exclusion criteria

1) Those who have factors other than dietary habits that greatly affect blood biomarker concentration (Habitual drinker or smoker, those who have an infectious disease within 1 month of the start of the study, those who take antibiotics within 1 month of the start of the study, those who have chronic digestive disorders)
2) Those who have factors other than blood biomarker concentration that greatly affect appetite (Those who eat less than two meals a day on some days, those who are undergoing hormone therapy [including steroid])
3) Those who may have adverse events when collecting blood (those who are sensitive to alcohol to the extent that alcohol disinfection is difficult, those who have skin diseases on their fingers, Those who with severe anemia)
4) Those who are unable to draw the required amount of blood (100 microL) at the screening
5) Those who may develop allergies due to ingestion of the test foods
6) Subjects who regularly use medicines, health foods, and supplements (Except for those who can stop taking health foods and supplements approximately one week prior to the start of the study)
7) Those who habitually consume (at least twice a week) foods containing the same active ingredients as the test foods and beverages (Except for those who can reduce the intake of these foods to less than twice a week for both about 1 week prior to the start of the study)
8) Those who participated in other human studies within 1 month of the start of this study
9) Pregnant or lactating women, women who expect to be pregnant during this study or may be pregnant
10) Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator

Target sample size

44


Research contact person

Name of lead principal investigator

1st name Yusuke
Middle name
Last name Ushida

Organization

KAGOME CO., LTD.

Division name

Nature & Wellness Research Department, Innovation Division

Zip code

329-2762

Address

17 Nishitomiyama, Nasushiobara, Tochigi, Japan

TEL

0287-36-2935

Email

Yusuke_Ushida@kagome.co.jp


Public contact

Name of contact person

1st name Shigeru
Middle name
Last name Imai

Organization

Leverage Brain Inc.

Division name

Clinical Trial Department

Zip code

150-0002

Address

Shibuya 1-4-7 Shibuya-ku, Tokyo, Japan

TEL

080-7290-0404

Homepage URL


Email

imai@levbrain.com


Sponsor or person

Institute

KAGOME CO., LTD.

Institute

Department

Personal name



Funding Source

Organization

KAGOME CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Leverage Brain Inc.

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Japan Conference of Clinical Research

Address

1-13-23 Minamiikebukuro Toshima-ku, Tokyo, Japan

Tel

03-6868-7022

Email

jccr-info@cts-smo.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

渋谷神山町診療所(東京都)/ Shibuya Kamiyamacho clinic(Tokyo)


Other administrative information

Date of disclosure of the study information

2022 Year 09 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2022 Year 09 Month 12 Day

Date of IRB

2022 Year 09 Month 15 Day

Anticipated trial start date

2022 Year 09 Month 21 Day

Last follow-up date

2022 Year 12 Month 02 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 09 Month 20 Day

Last modified on

2023 Year 12 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055799


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name